Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

responses observed in this trial represent a clinically meaningful outcome for many of these difficult-to-treat AML patients. As a single-agent, single-infusion therapy, Cloretazine(R) (VNP40101M) has the potential to be an important new treatment option for older patients with poor-risk AML."

Alan Kessman, Chief Executive Officer, said, "These interim data continue to demonstrate Cloretazine(R) (VNP40101M)'s potential utility in a patient population which represents an unmet medical need." He added, "It continues to be our plan to file a new drug application with the U.S. Food and Drug Administration in 2008 based on the data from this trial and our previous Phase II trial in elderly patients with AML."

The pivotal Phase II trial started in May 2006 and was conducted in 25 sites in North America and Europe. Enrollment of the primary study was completed in August 2007. The trial remains open at selected sites in order to collect QT/QTc interval data in an electrocardiogram sub-study in accordance with FDA/ICH guidelines.

The study was designed for patients with untreated de novo AML who are age 60 or older and have at least one of the following adverse prognostic factors: age greater or equal to 70, ECOG performance status equal to 2, unfavorable cytogenetics or organ dysfunction. The primary endpoint of the trial is the overall complete response rate measured as either complete remission (CR) or CRp, a complete response with incomplete platelet recovery. Secondary endpoints are progression-free survival, leukemia-free survival, overall survival and the toxicity of Cloretazine(R) (VNP40101M) in this patient population.

Patients receive induction therapy of 600 mg/m2 of Cloretazine(R) (VNP40101M) in a sixty-minute infusion. Second induction is permitted between days 35 and 60 in patients with bone marrow improvement but residual disease. Patients who respond can receive consolidation therapy with a continuous infusion of 400 mg/m2 of cytar
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Confirms Effectiveness of Autologous Therapy, DUSSELDORF, ... a two-year,representative study of knee osteoarthritis, published ... confirm,the safety and effectiveness of Orthokine therapy, ... own blood are,injected into the arthritic joint., ...
... Phase III Study to Explore the Effects of ... Calcitonin on Vertebral Fractures in Postmenopausal Women, ... (Nasdaq: EMIS ) announced today that Novartis ... III study exploring the,safety and efficacy of Salmon ...
Cached Medicine Technology:Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment 2
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) as,its ... announced transaction,between Takeda Pharmaceutical Company Limited and Alnylam. ... of future milestone and royalty,payments. This transaction further ...
... of almonds closer to that of roses or bananas? Weizmann ... for the first time that smells can be mapped and ... appeared recently in Nature Methods, may help scientists to unravel ... as potentially enabling odors to be digitized and transferred via ...
... Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) (,Lotus, or the ... China ("PRC"), today,announced that it will conduct a ... May 27, 2008 to discuss the first quarter ... and Chief Executive Officer of Lotus,Pharmaceuticals, will be ...
... ON, May 27 /PRNewswire-FirstCall/ - AlphaRx (OTC ... proprietary drug,delivery technology to develop novel formulations ... and USAMRIID (U.S. Army Medical Research Institute ... Research and,Development Agreement for Material Transfer (MTA). ...
... UCLA have identified a type of leukemia stem cell and ... blood stem cells to become cancerous. , The discovery may ... attacking the disease at its very root and killing the ... The study appears in the May 22, 2008 issue of ...
... Dozens of Videos from Doctors and Students at Seattle Children,s Hospital, Swedish ... ... Available,Videos Offer Insight and Advice on Topics Ranging from Pediatrics to Cancer ... Screening to Novel Surgical Techniques, NEW YORK, May 27 ...
Cached Medicine News:Health News:Isis to Receive $4.6 Million From Alnylam 2Health News:Isis to Receive $4.6 Million From Alnylam 3Health News:Weizmann Institute scientists produce the first smell map 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 3Health News:AlphaRx Signs Cooperative Research and Development Agreement with US Army 2Health News:UCLA researchers identify leukemia stem cells 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 3
... The aliquot! The aliquot from Genetix is ... with 96, 384, and 1536 well microplates. ... backfilling facility and optional microplate stacker, the ... low volume dispensing needs. The aliQuot's compact ...
... is a compact and self-contained multichannel ... a unique flow-through device, which allows ... wash system. Optional refill system ... Will be upgradable to with ...
... Aquarius 96 is a compact and self-contained ... fixed tip manifold can be used in ... washed in the optional active wash system. ... dust and adds safety. ...
... ideal system for fast, accurate filling of 96 ... valve controlled dispensing mechanism, ensures that no liquid ... components that come into contact with the liquid ... The unique compact design saves valuable bench space ...
Medicine Products: